We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Halozyme Therapeutics, Inc.
Health Care · Biotechnology
Structural: ENHANZE is the de facto standard for SC-converting blockbuster biologics - 13+ partnered programs, royalty stack compounds as each partner launches new SC formulations and gets uptake. Royalty model = ~85% gross margins, minimal R&D burden vs.
owning a pipeline. Mid-2027 cliff: Darzalex SC composition-of-matter IP expires, which threatens the largest royalty stream ($JNJ Darzalex Faspro ~50% of royalty revenue).
(1) Royalty mix shifts as $ARGX Vyvgart Hytrulo, $BMY Opdivo SC, $ROG Ocrevus SC, $JNJ Rybrevant SC ramp - reduces Darzalex concentration. (2) ENHANZE platform IP extends beyond 2030 on newer co-formulations (different patent families than Darzalex 2027 cliff).
(3) Buybacks aggressive - board has repeatedly authorized large repurchase programs, float shrinking. (4) Pharma pipeline of IV-to-SC conversions still has multi-year runway (oncology, immunology, rare disease). (5) Auto-injector business (Antares) adds proprietary product revenue, less royalty-cliff-sensitive.
(1) Darzalex 2027 IP cliff is the dominant overhang - biosimilar SC versions could compress the largest royalty line. (2) Partner concentration: $JNJ + $BMY + $ROG = bulk of revenue, partner business decisions (pricing, switching IV-only) flow straight through.
(3) Alternative SC delivery tech (Merck's MK-1084 platform, $ALT competing hyaluronidase variants) could erode pricing power on new deals. (4) Litigation/patent challenges from biosimilar makers ongoing. (5) Royalty model means no upside from operational leverage - top-line is capped by partner sell-through.